Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056418 | 0.95 | PRMT5 (0.34) | SLC1A3SLC1A2SLC1A1PRMT5WDR77 | |
| SCHEMBL10228451 | 0.93 | PRMT5 (0.36) | SLC1A3SLC1A2SLC1A1PRMT5WDR77 | |
| SCHEMBL130874 | 0.90 | — | — | |
| SCHEMBL14265633 | 0.82 | RHEB (0.31) | — | |
| SCHEMBL18580427 | 0.82 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1PRMT5WDR77 | |
| SCHEMBL18580426 | 0.82 | SLC1A3 (0.38) | SLC1A3SLC1A2SLC1A1PRMT5WDR77 | |
| SCHEMBL12687468 | 0.80 | SPHK2 (0.36) | PRMT5WDR77ADRB1CYP2D6MEN1 | |
| SCHEMBL8977001 | 0.80 | — | — | |
| SCHEMBL12687460 | 0.80 | SPHK2 (0.36) | PRMT5WDR77ADRB1CYP2D6MEN1 | |
| SCHEMBL10307716 | 0.80 | TDP1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940722-B2 | Compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORγ, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2015-01-27 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2013-02-28 | — | — | US | disclosed |
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | PHENEX PHARMACEUTICALS AG (DE) | 2013-02-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8084472-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20090186888-A1 | NOVEL FUSED PYRROLOCARBAZOLES | CEPHALON, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-7514440-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-20070203135-A1 | Novel Fused Pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7241779-B2 | Fused pyrrolocarbazoles | CEPHALON, INC. (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053380-A1 | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune disease | RORB, RORC, RORA | SLC1A3 2130/4885SLC1A2 3151/4885SLC1A1 1811/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | SLC1A3 4804/4885SLC1A2 4730/4885SLC1A1 4670/4885 |
| US-20090186888-A1 | NOVEL FUSED PYRROLOCARBAZOLES | PC, PYCR1, CYP11B2 | SLC1A3 2991/4885SLC1A2 3306/4885SLC1A1 2703/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | SLC1A3 1952/4885SLC1A2 2234/4885SLC1A1 1437/4885 |
| US-20070203135-A1 | Novel Fused Pyrrolocarbazoles | PC, PYCR1, CYP11B2 | SLC1A3 2991/4885SLC1A2 3306/4885SLC1A1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.